Paliperidone for irritability in autistic disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 1, 2010, Pages 75-78

  Stigler, Kimberly A ^a   Erickson, Craig A ^a   Mullett, Jennifer E ^a   Posey, David J ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DIAZEPAM; GUANFACINE; NALTREXONE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; ADULT; AGGRESSION; ANGER; AUTISM; AUTOMUTILATION; CASE REPORT; COMORBIDITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IRRITABILITY; LETTER; MALE; MENTAL DEFICIENCY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRRITABLE MOOD; ISOXAZOLES; MALE; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77249106095     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0019     Document Type: Letter

References (19)

1. th Edition, Text Revision. Washington (DC): American Psychiatric Association, 2000.
2. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety, and early response of paliperidone extendedrelease tablets: Results of a 6-week, randomized, placebocontrolled study. Schizophr Res 93:117-130, 2007.
3. Ereshefsky L, Mascarenas CA: Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64:18-23, 2003.
4. Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33:155-159, 1997.
5. Guy W. ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338). Washington (DC): DHEW, NIMH, 1976.
6. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 90:147-164, 2007.
7. Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L: Pharmacokinetics and D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. EurNeuropsychopharmacol 15(Suppl 3):S386, 2005.
8. Lord C, Rutter M, Le Couteur AM: Autism diagnostic interviewrevised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 27:659-685, 1994.
9. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62:1363-1370, 2007.
10. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206-1214, 2001.
11. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label investigation. J Am Acad Child Adolesc Psychiatry 36:685-693, 1997.
12. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B: Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162:1142-1148, 2005.
13. Meltzer HY, Bobo WV, Nuamah F, Lane R, Hough D, Kramer M, Eerdekens M: Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 69:817-829, 2008.
14. Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-376, 1998.
15. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
16. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunber F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-641, 2004.
17. Schooler N, Gharabawi G, Bossie C, et al. A virtual comparison of paliperidone ER and oral risperidone in patients with schizophrenia. Chicago (Illinois): Collegium Internationale Neuro-Psychopharmacologicum, 2006.
18. Stigler KA, McDougle CJ: Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatric Clin N Am 17:739-752, 2008.
19. Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M: Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol 15(Suppl 3):S191-S192, 2005.